Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05905133
Other study ID # CBP-201-CN003
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date July 15, 2023
Est. completion date June 30, 2024

Study information

Verified date December 2023
Source Suzhou Connect Biopharmaceuticals, Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a single-arm, open-label, multi-center clinical study designed to assess the safety and efficacy of CBP-201 in eligible subjects with moderate to severe Atopic Dermatitis.


Description:

The study includes a screening period, a treatment period and a follow-up period. The subjects will receive a subcutaneous injection of CBP-201 600 mg (4 mL in total, 2 injections of 2 mL each in different sites) on Day1, begin to receive a subcutaneous injection of CBP-201 300 mg (2 mL) from Week2, and receive CBP-201 300 mg (2 mL) every 2 weeks thereafter until Week10.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 360
Est. completion date June 30, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. 18 = age = 75 years at the screening visit, male or female. 2. Diagnosed with atopic dermatitis (according to the American Academy of Dermatology's Guidelines of care for the management of atopic dermatitis, 2014[1]) at the time of screening, and meeting all the 4 criteria below: 1. Suffering from the disease for more than 1 year at the time of screening; 2. At the screening and baseline visit, IGA score = 3 (according to the validated Investigator Global Assessment for Atopic Dermatitis [vIGA-AD™] scale); 3. EASI score = 12; 4. Percentage of total BSA affected by AD = 10%. 3. Female subjects of childbearing potential (FCBP) and male subjects who have not undergone vasectomy must agree to take highly effective contraceptive measures during the entire study period (from the signing of informed consent forms (ICFs) to the 8-week follow-up period after discontinuation of study drug). Postmenopausal women (determined by testing follicle stimulating hormone [FSH]; defined as the women who have had amenorrhea for at least 12 consecutive months without using drugs known to cause amenorrhea, and have a recorded FSH level greater than 40 mIU/mL or in the postmenopausal range) and women with a record of surgical sterilization (i.e., tubal ligation or hysterectomy or bilateral oophorectomy) before the screening visit can be considered infertile. Highly effective contraceptive measures include: i. Abstinence (acceptable only if it is part of the subject's routine lifestyle); ii. Hormones (oral, patch, ring, injection, implant) combined with male condoms. This measure must be used at least 30 days before the first study drug administration. Otherwise, another acceptable method of contraception must be used; iii. Intrauterine device (IUD) combined with male condoms. 4. Subjects are willing and able to comply with study visits and related procedures. 5. Subjects have the ability to learn the study requirements and process, and voluntarily take part in the clinical trial and sign an ICF. Exclusion Criteria: 1. Received prior treatment with anti-interleukin-4 receptor a (IL-4Ra)/anti-interleukin-13 (IL-13) antibodies with a poor response (including treatment failure or development of unacceptable treatment-related adverse reactions). 2. Have received any of the following topical treatments within 2 weeks before D1 visit: phosphodiesterase-4 (PDE-4) inhibitors, Janus kinase (JAK) inhibitors, or aromatic hydrocarbon receptor agonists. 3. Have received systemic treatment with corticosteroids (except for corticosteroid inhalers and nasal sprays) or other immunosuppressive/immunomodulatory agents (including but not limited to cyclosporine, mycophenolate mofetil, azathioprine, methotrexate, JAK inhibitors, and various biological agents) within 2 weeks before D1 visit or 5 drug half-lives (if known), whichever is longer. 4. Have received treatment with immune cell depletion agents (e.g., rituximab) within 6 months before D1 visit. 5. Have received any investigational drug/treatment within 4 weeks before D1 visit or 5 drug half-lives (if known), whichever is longer. 6. Other skin complications in addition to AD that may interfere with the study assessments. 7. There is a known or suspected history of immunosuppression/immunodeficiency within 6 months before D1 visit (including but not limited to a history of invasive opportunistic infections, such as aspergillosis, coccidiosis, histoplasmosis, acquired immunodeficiency syndrome (AIDS), listeriosis, or Pneumocystis, even if the infection has subsided), or there is an abnormally frequently recurrent or persistent infection. 8. Received systemic treatment with anti-infective drugs (including but not limited to antibiotics, antiviral drugs, antiparasitic drugs, antiprotozoal drugs, or antifungal drugs) due to acute or chronic infection within 1 week before D1 visit (after the infection subsides, the subjects can be rescreened). 9. History of malignant tumor within 5 years before D1 visit (except for completely cured cervical carcinoma in situ or non-metastatic cutaneous squamous cell carcinoma or basal cell carcinoma). 10. History of parasite infection within 6 months before D1 visit. 11. Positive for hepatitis B surface antigen (HBsAg), or positive for hepatitis B core antibody (HBcAb) and HBV-DNA, or positive for hepatitis C antibody and HCV ribonucleic acid (RNA) polymerase chain reaction, or serologically positive for human immunodeficiency virus (HIV) at the screening visit. 12. Subjects with active tuberculosis, latent tuberculosis, or a history of nontuberculous mycobacterial infection at screening; Note: - Unless there is a clear medical record proving that the subject has received adequate treatment and is currently able to start receiving biological treatment (based on the medical judgment of the investigator and/or infectious disease specialist); - If needed, an interferon gamma release assay may be used to assist diagnosis of suspected tuberculosis. 13. Any of the following laboratory test abnormalities at the screening visit: 1. Aspartate aminotransferase or alanine aminotransferase > 2 times the upper limit of normal (ULN); 2. Total bilirubin > 1.5 × ULN; 3. Serum creatinine > 1.2 × ULN; 4. White blood cell count < 3.0 × 109/L or = 14 × 109/L; Note: If the subjects have the above laboratory test abnormalities at screening, after being assessed as necessary by the investigator, they are allowed to receive a retest on another day within 28 days of the screening period, and those qualified for the retest are permitted to be enrolled (it is forbidden to conduct drug intervention for those laboratory test abnormalities before retest). 14. History of hypersensitivity to L-histidine, trehalose or Tween (polysorbate) 80, or systemic hypersensitivity reactions to any biological agents (except local injection site reactions). 15. History of alcohol or drug abuse within 2 years before D1 visit. 16. Have been vaccinated with (attenuated) live vaccine within 8 weeks before D1 visit, or planning to be vaccinated during the study period. 17. Planning to undergo major surgical operations during the study period. 18. Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period. 19. Any other conditions (e.g., those may increase the risks of the subjects, or may affect/interfere with the assessment of the study) that the investigator deems unsuitable for participation in this study, including but not limited to: prior or current physical or mental illness, clinically significant physical examination results, vital signs, or safety laboratory test abnormalities at screening. The specific reasons for subjects excluded due to this criterion will be indicated in the study documents (including medical records and electronic case report form (eCRF)).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
CBP-201
subcutaneous injection

Locations

Country Name City State
China Connect Investigative Site 24 Baotou Nei Monggol
China Connect Investigative Site 01 Beijing Beijing
China Connect Investigative Site 41 Beijing Beijing
China Connect Investigative Site 26 Changsha Hunan
China Connect Investigative Site 23 Chengdu Sichuan
China Connect Investigative Site 30 Dongying Shandong
China Connect Investigative Site 14 Fuzhou Fujian
China Connect Investigative Site 25 Fuzhou Fujian
China Connect Investigative Site 03 Guangzhou Guangdong
China Connect Investigative Site 11 Guangzhou Guangdong
China Connect Investigative Site 13 Guangzhou Guangdong
China Connect Investigative Site 20 Guangzhou Guangdong
China Connect Investigative Site 16 Haikou Hainan
China Connect Investigative Site 17 Haikou Hainan
China Connect Investigative Site 07 Hangzhou Zhejiang
China Connect Investigative Site 08 Hangzhou Zhejiang
China Connect Investigative Site 33 Hangzhou Zhejiang
China Connect Investigative Site 37 Hangzhou Zhejiang
China Connect Investigative Site 40 Jiangxi Nanchang
China Connect Investigative Site 21 Jinan Shandong
China Connect Investigative Site 35 Jinan Shandong
China Connect Investigative Site 34 Nanjing Jiangsu
China Connect Investigative Site 31 Nanning Guangxi
China Connect Investigative Site 19 Nanyang Henan
China Connect Investigative Site 32 Ningbo Zhejiang
China Connect Investigative Site 36 Shanghai Shanghai
China Connect Investigative Site 29 Shenyang Liaoning
China Connect Investigative Site 22 Shenzhen Guangdong
China Connect Investigative Site 39 Suzhou Jiangsu
China Connect Investigative Site 10 Taiyuan Shanxi
China Connect Investigative Site 02 Tianjin Tianjin
China Connect Investigative Site 09 Ürümqi Xinjiang
China Connect Investigative Site 27 Wuhan Hubei
China Connect Investigative Site 06 Xi'an Shanxi
China Connect Investigative Site 28 Yichang Hubei
China Connect Investigative Site 18 Yinchuan Ningxia
China Connect Investigative Site 15 Yuncheng Shanxi
China Connect Investigative Site 05 Zhenjiang Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Suzhou Connect Biopharmaceuticals, Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of treatment-emergent adverse events (TEAEs) cases/person-years From Day 1 study drug first administrated to Week 20
Secondary Incidence of treatment-related treatment-emergent adverse events (TEAEs) cases/person-years From Day 1 study drug first administrated to Week 20
Secondary Incidence of serious adverse events (SAEs) cases/person-years From Day 1 study drug first administrated to Week 20
Secondary Incidence of treatment-related serious adverse events (SAEs) cases/person-years From Day 1 study drug first administrated to Week 20
Secondary Incidence of adverse events of special interest (AESIs) cases/person-years From Day 1 study drug first administrated to Week 20
Secondary Abnormal changes in vital signs Vital signs (VS): including body temperature, respiration rate, blood pressure, and heart rate. Pre-dose, Day1, Day15, Day29, Day43, Day57, Day71, Day85, Day113, Day141
Secondary Abnormal changes in physical examination Physical examination included are as follows: general appearance, skin, ears/nose/throat, head and neck, cardiovascular system, respiratory system, abdomen, limbs, lymph nodes, musculoskeletal and nervous systems. Pre-dose, Day85, Day141
Secondary Abnormal changes in laboratory tests: Hematology White blood cell count, Hemoglobin, Hematocrit, Red blood cell count, Platelet count, Neutrophil percentage, Lymphocyte percentage, Monocyte percentage, Basophil percentage, Eosinophil percentage, Absolute neutrophil count, Absolute lymphocyte count, Absolute monocyte count, Absolute eosinophil count, Absolute basophil count Pre-dose, Day1, Day15, Day29, Day57, Day85, Day141
Secondary Abnormal changes in laboratory tests: Blood biochemistry Sodium, Potassium, Calcium, Chlorine, Serum urea/urea nitrogen, Creatinine, Glucose, Total protein, Albumin, Total bilirubin, Alanine aminotransaminase, Aspartate aminotransferase, ?-glutamyltransferase, Alkaline phosphatase, Lactate dehydrogenase, Creatine phosphokinase, Total cholesterol, Low-density lipoprotein, High-density lipoprotein Pre-dose, Day1, Day15, Day29, Day57, Day85, Day141
Secondary Abnormal changes in laboratory tests: Urinalysis Urine bilirubin, Urine red blood cells, Urine white blood cells, Urine glucose, Urine ketone, Urine nitrite, Urine pH, Urine protein, Urine specific gravity, Urobilinogen, Microscopic examination (if necessary) Pre-dose, Day1, Day15, Day29, Day57, Day85, Day141
Secondary Abnormal changes in electrocardiogram (ECG) parameters ECG variables include ventricular heart rate and PR, QRS, QT, and QTcF intervals. Pre-dose, Day1, Day141
Secondary Proportion of subjects achieving greater than or equal to 75% improvement in Eczema Area and Severity Index (EASI-75) The Eczema Area and Severity Index (EASI) scale quantifies the severity and extent of Atopic Dermatitis, as well as the severity of erythema, infiltration, excoriation, and lichenification of the four anatomical regions-head and neck, trunk, upper extremities, and lower extremities. Day1, Day15, Day29, Day57, Day85, Day113, Day141
Secondary Proportion of subjects whose Investigator Global Assessment (IGA) score is 0-1 and decreased by = 2 points from baseline The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) Scale is a 5-point classification scale based on the overall appearance of the skin lesions at a specific time point. Day1, Day15, Day29, Day57, Day85, Day113, Day141
Secondary Proportion of subjects achieving greater than or equal to 50% improvement in Eczema Area and Severity Index (EASI-50) The Eczema Area and Severity Index (EASI) scale quantifies the severity and extent of Atopic Dermatitis, as well as the severity of erythema, infiltration, excoriation, and lichenification of the four anatomical regions-head and neck, trunk, upper extremities, and lower extremities. Day1, Day15, Day29, Day57, Day85, Day113, Day141
Secondary Proportion of subjects achieving greater than or equal to 90% improvement in Eczema Area and Severity Index (EASI-90) The Eczema Area and Severity Index (EASI) scale quantifies the severity and extent of Atopic Dermatitis, as well as the severity of erythema, infiltration, excoriation, and lichenification of the four anatomical regions-head and neck, trunk, upper extremities, and lower extremities. Day1, Day15, Day29, Day57, Day85, Day113, Day141
Secondary Proportion of subjects achieving 100% improvement in Eczema Area and Severity Index (EASI-100) The Eczema Area and Severity Index (EASI) scale quantifies the severity and extent of Atopic Dermatitis, as well as the severity of erythema, infiltration, excoriation, and lichenification of the four anatomical regions-head and neck, trunk, upper extremities, and lower extremities. Day1, Day15, Day29, Day57, Day85, Day113, Day141
Secondary Proportion of subjects whose IGA score is decreased by = 2 points from baseline The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) Scale is a 5-point classification scale based on the overall appearance of the skin lesions at a specific time point. Day1, Day15, Day29, Day57, Day85, Day113, Day141
Secondary Proportion of subjects with IGA score = 2 (equivalent to reaching a low disease activity state) The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™) Scale is a 5-point classification scale based on the overall appearance of the skin lesions at a specific time point. Day1, Day15, Day29, Day57, Day85, Day113, Day141
Secondary Proportion of subjects whose weekly average Peak Pruritus Numerical Rating Scale (PP-NRS) is decreased by = 3 points from baseline Peak Pruritus Numerical Rating Scale (PP-NRS) is a single self-reported item designed to measure the peak pruritus or the "worst" pruritus in the previous 24 hours. Day1, Day15, Day29, Day43, Day57, Day71, Day85, Day113, Day141
Secondary Proportion of subjects whose weekly average Peak Pruritus Numerical Rating Scale (PP-NRS) is decreased by = 4 points from baseline Peak Pruritus Numerical Rating Scale (PP-NRS) is a single self-reported item designed to measure the peak pruritus or the "worst" pruritus in the previous 24 hours. Day1, Day15, Day29, Day43, Day57, Day71, Day85, Day113, Day141
Secondary Change and percentage change in the EASI score from baseline The Eczema Area and Severity Index (EASI) scale quantifies the severity and extent of Atopic Dermatitis, as well as the severity of erythema, infiltration, excoriation, and lichenification of the four anatomical regions-head and neck, trunk, upper extremities, and lower extremities. Day1, Day15, Day29, Day57, Day85, Day113, Day141
Secondary Change and percentage change in the weekly average PP-NRS from baseline Peak Pruritus Numerical Rating Scale (PP-NRS) is a single self-reported item designed to measure the peak pruritus or the "worst" pruritus in the previous 24 hours. Day1, Day15, Day29, Day43, Day57, Day71, Day85, Day113, Day141
Secondary Change and percentage change in the body surface area (BSA) affected by Atopic Dermatitis from baseline The "Rule of Nines" is used to estimate the maximum percentage of Atopic Dermatitis-affected body surface area (BSA): head and neck [9%], anterior trunk [18%], back [18%], upper limbs [18%], lower limbs [36%], and genitals [1%]. Day1, Day15, Day29, Day57, Day85, Day113, Day141
Secondary Change and percentage change in the Dermatology Life Quality Index (DLQI) score from baseline Dermatology Life Quality Index (DLQI) is a questionnaire containing 10 items to assess the impact of Atopic Dermatitis on quality of life (QOL) in the past week, and the scores range from 0 (no disease) to 30 (severe disease); the higher the score, the worse the quality of life. Day1, Day15, Day29, Day57, Day85, Day113, Day141
Secondary Proportion of subjects receiving concomitant medications for the treatment of the disease under study (Atopic Dermatitis) except emollients; the proportion will be summarized separately by all concomitant medications and the ATC2 codes for concomitant medications from Day1 to Week12
Secondary Proportion of subjects receiving concomitant medications for the treatment of the disease under study (Atopic Dermatitis) prohibited by the protocol (except emollients; the proportion will be summarized separately by all concomitant medications, local therapy, systemic treatment, and the ATC2 codes for concomitant medications) from Day1 to Week12
Secondary Proportion of subjects receiving topical corticosteroids (TCS) for the treatment of the disease under study (Atopic Dermatitis) If topical corticosteroids (TCS) is considered necessary by the investigator. from Day1 to Week12
Secondary Duration of TCS use for the treatment of the disease under study (Atopic Dermatitis) days/person-years from Day1 to Week12
Secondary Percentage of subjects positive for anti-drug antibody (ADA) and ADA titer range Descriptive statistics will be used to summarize the baseline values of related measurements (ADA, NAb) and the changes from baseline to each visit. Day1, Day15, Day29, Day57, Day85, Day141
Secondary Percentage of subjects positive for neutralizing antibody (NAb) in subjects positive for ADA Descriptive statistics will be used to summarize the baseline values of related measurements (ADA, NAb) and the changes from baseline to each visit. Day1, Day15, Day29, Day57, Day85, Day141
See also
  Status Clinical Trial Phase
Completed NCT05018806 - Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis Phase 2
Terminated NCT03847389 - Clobetasol Topical Oil for Children With Moderate to Severe Atopic Dermatitis Phase 1/Phase 2
Completed NCT04090229 - A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis Phase 1
Active, not recruiting NCT05388760 - Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1) Phase 2
Completed NCT05530707 - Evaluation of Acceptability, Skin Barrier Restoration and Balance of Atopic Skin Using Moisturizer N/A
Completed NCT02595073 - Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone (DSXS) With Atopic Dermatitis Phase 3
Recruiting NCT05509023 - Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD) Phase 2
Recruiting NCT05048056 - Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis Phase 2
Completed NCT04598269 - Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis Phase 2
Recruiting NCT03936335 - An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Recruiting NCT05029895 - A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)
Terminated NCT03654755 - Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis Phase 2
Completed NCT04556461 - Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier Function Phase 2
Recruiting NCT04818138 - BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort N/A
Completed NCT03719742 - A Clinical Study to Evaluate the Safety and Efficacy of a Baby Cleanser and a Moisturizer N/A
Completed NCT05375955 - A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis. Phase 2
Completed NCT03441568 - In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control N/A
Recruiting NCT06366932 - Optimization of Atopic Dermatitis Treatment That Requires Second-line Systemic Therapy Through Predictive Models Phase 4
Completed NCT03304470 - A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis Phase 2